Precision BioSciences Inc. Form 8-K Summary
Business Context and Reporting Period
Precision BioSciences, Inc. (DTIL) filed a Current Report on Form 8-K on May 5, 2026. The filing announces the financial results for the quarter ended March 31, 2026. The full details of these results are contained in a press release furnished as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text provided.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the incorporated press release for comparative financial analysis.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, management commentary, risk factors, or details on unusual items. The report explicitly states that the information in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting the legal liability of the incorporated press release content within this specific document.
Key Facts for Investor Verification
- Verify the specific revenue and net loss figures for the quarter ended March 31, 2026, in the attached press release (Exhibit 99.1).
- Confirm the company's cash position and burn rate as of the reporting date.
- Review the press release for any updates on clinical trial progress or commercial partnerships.
- Note that the financial data in this 8-K is furnished by reference and not directly filed within the text of this report.